Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionProduct descriptionProduct information

Contraindications/Warnings/Precautions/Adverse effects

7 evidence topics · 1 source

Warnings and precautions
FDA-approved prescribing information for darovasertib

Not applicable.

Crizotinib label: hepatotoxicity, with liver function monitoring every 2 weeks for the first 2 months
Crizotinib label: QT interval prolongation, with ECG and electrolyte monitoring
Crizotinib label: bradycardia, with heart rate and blood pressure monitoring and review of bradycardic and antihypertensive medications

“Symptomatic bradycardia can occur in patients receiving XALKORI.” (opens the source at this quote in a new tab)

“Across clinical trials in patients with NSCLC, bradycardia occurred in 13% of 1719 patients treated with XALKORI.” (opens the source at this quote in a new tab)

“Grade 3 syncope occurred in 2.4% of XALKORI-treated patients and in 0.6% of the chemotherapy-treated patients” (opens the source at this quote in a new tab)

“Avoid using XALKORI in combination with other medications known to cause bradycardia (e.g., beta-blockers, nondihydropyridine-calcium channel blockers, clonidine, and digoxin) to the extent possible.” (opens the source at this quote in a new tab)

“Monitor heart rate and blood pressure regularly.” (opens the source at this quote in a new tab)

“If bradycardia occurs, re-evaluate for the use of concomitant medications known to cause bradycardia.” (opens the source at this quote in a new tab)

“Adult patients: Heart rate less than 60 beats per minute (bpm)” (opens the source at this quote in a new tab)

“Evaluate concomitant medications known to cause bradycardia, as well as antihypertensive medications.” (opens the source at this quote in a new tab)

“If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume at previous dose upon recovery to asymptomatic bradycardia or to the age-specific heart rate provided above.” (opens the source at this quote in a new tab)

“If no contributing concomitant medication is identified, or if contributing concomitant medications are not discontinued or dose adjusted, resume at reduced dose upon recovery to asymptomatic bradycardia or to the age-specific heart rate provided above.” (opens the source at this quote in a new tab)

Crizotinib label: severe visual loss and visual disorders, with monthly assessment of visual symptoms